![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 07, 2013 10:50:59 PM
Includes all the latest data, timelines, market size potential and clearly articulates commercialization readiness and potential for LymPro and MANF.
There are so many activities in play across their portfolio ....it is only a matter of time before investors will recognize the enormous potential this company has with its Science.
One key note: Once the Performance analysis study is completed in Q3 for LymPro...it will open the door to partnership possibilities with any Pharma. or Diagnostic based companies. Moreover, AMBS has retained full ownership of the LymPro asset; which can allow them to negotiate with any 3rd party to partner with them....so keep in mind that BD will most likely get and take the first shot (assuming the test meets the necessary milestones...don't rule out that Lilly or another large Pharma. could step in as well.
These are truly exciting times for this organization; I believe its a steal to buy and/or accumulate this stock ahead of a very busy 3rd quarter (and beyond).
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM